Spots Global Cancer Trial Database for APG-2449 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: APG-2449 in Patients With Advanced Solid Tumors
Official Title: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors
Study ID: NCT03917043
Interventions
Study Description
Brief Summary: APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Cancer Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun-Yat Sen University Cancer Center, Guangzhou, Guangdong, China
The First affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Henan Provincial Oncology Hospital, Zhengzhou, Henan, China
Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Provincial Oncology Hospital, Changsha, Hunan, China
West China hospital of Sichuan University, Chengdu, Sichuan, China
Zhejiang Provincial Oncology Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Li Zhang, Professor
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
